Analysts Offer Predictions for Nuwellis, Inc.’s Q2 2024 Earnings (NASDAQ:NUWE)

Nuwellis, Inc. (NASDAQ:NUWE) – Research analysts at Roth Capital issued their Q2 2024 earnings estimates for shares of Nuwellis in a report issued on Monday, July 29th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings per share of ($9.49) for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($7.00) per share. Roth Capital also issued estimates for Nuwellis’ Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.48) EPS, FY2024 earnings at ($7.00) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($0.06) EPS, FY2027 earnings at $1.58 EPS and FY2028 earnings at $3.54 EPS.

Separately, Roth Mkm began coverage on shares of Nuwellis in a report on Monday. They set a “buy” rating and a $17.00 price target for the company.

Nuwellis Price Performance

Shares of NASDAQ NUWE opened at $2.76 on Wednesday. The company has a 50 day simple moving average of $5.72 and a 200-day simple moving average of $11.24. The company has a market capitalization of $1.79 million, a P/E ratio of -0.01 and a beta of 0.44. Nuwellis has a 1 year low of $2.19 and a 1 year high of $92.75.

Nuwellis (NASDAQ:NUWE) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($21.00) earnings per share (EPS) for the quarter. The firm had revenue of $1.86 million for the quarter. Nuwellis had a negative return on equity of 316.90% and a negative net margin of 202.97%.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.